Niagen Bioscience NAGE Estimates

NASDAQ NAGE
$3.13 +0.03 (+0.80%)
As of: Sep 4, 2026 · 2:19 PM EDT
Analyst Estimates

Niagen Bioscience, Inc. Revenue Estimates

Periods 27
Next Period Q3 26
Consensus 39.16 M

Analysts expect Niagen Bioscience, Inc. to report revenue of 39.16 M for Q3 26, against a range of 35.86 M to 42.46 M. The most recent reported quarter, Q2 26, came in at 29.79 M, a 1.4% beat against the 29.37 M consensus.

Metric Q2 24Q3 24Q4 24Q1 25Q2 25Q3 25Q4 25Q1 26Q2 26Q3 26Q4 26Q1 27Q2 27Q3 27Q4 27Q1 28Q2 28Q3 28Q4 28Q1 29Q2 29Q3 29Q4 29Q1 30Q2 30Q3 30Q4 30
Reported (Actual) 22.74 M25.58 M29.13 M30.48 M31.12 M33.99 M33.84 M31.47 M29.79 M--------
High Estimate 23.05 M25.08 M28.01 M27.67 M27.70 M35.09 M34.53 M35.31 M30.35 M42.46 M42.77 M42.60 M40.87 M48.46 M53.40 M43.73 M44.05 M
Low Estimate 21.04 M20.95 M23.48 M22.88 M25.97 M30.90 M30.58 M30.47 M28.38 M35.86 M38.53 M35.62 M35.38 M40.81 M48.47 M38.99 M38.47 M
Consensus Estimate 22.05 M23.02 M25.74 M25.28 M26.84 M32.99 M32.56 M32.89 M29.37 M39.16 M40.65 M39.11 M38.13 M44.63 M50.94 M41.36 M41.26 M
Analyst Estimates

Niagen Bioscience, Inc. Earnings Per Share (EPS) Estimates

Periods 27
Next Period Q3 26
Consensus 0.05

Analysts expect Niagen Bioscience, Inc. to report earnings per share of 0.05 for Q3 26, against a range of 0.05 to 0.05. The most recent reported quarter, Q2 26, came in at 0.01, a 21.4% beat against the 0.01 consensus.

Metric Q2 24Q3 24Q4 24Q1 25Q2 25Q3 25Q4 25Q1 26Q2 26Q3 26Q4 26Q1 27Q2 27Q3 27Q4 27Q1 28Q2 28Q3 28Q4 28Q1 29Q2 29Q3 29Q4 29Q1 30Q2 30Q3 30Q4 30
Reported (Actual) 0.000.030.090.060.040.050.050.070.01--------
High Estimate -0.020.010.020.020.010.020.020.080.010.050.070.050.020.060.080.100.05
Low Estimate -0.020.010.020.020.010.020.020.060.010.050.070.050.020.060.080.080.05
Consensus Estimate -0.020.010.020.020.010.020.020.070.010.050.070.050.020.060.080.090.05